EP1791528A1 - Lyophilisat enthaltend n-diaminomethylen-2-methyl-4,5-di-(methylsulfonyl)-benzamid - Google Patents

Lyophilisat enthaltend n-diaminomethylen-2-methyl-4,5-di-(methylsulfonyl)-benzamid

Info

Publication number
EP1791528A1
EP1791528A1 EP05779438A EP05779438A EP1791528A1 EP 1791528 A1 EP1791528 A1 EP 1791528A1 EP 05779438 A EP05779438 A EP 05779438A EP 05779438 A EP05779438 A EP 05779438A EP 1791528 A1 EP1791528 A1 EP 1791528A1
Authority
EP
European Patent Office
Prior art keywords
lyophilisate
methyl
benzamide
diaminomethylene
methylsulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05779438A
Other languages
German (de)
English (en)
French (fr)
Inventor
Hanns-Christian Mahler
Rita Heckmann
Dorothee Kress
Dirk Schiroky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of EP1791528A1 publication Critical patent/EP1791528A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Definitions

  • Example 4 The preparation and reconstitution of the lyophilisate is carried out analogously to Example 1.
  • Example 4 The preparation and reconstitution of the lyophilisate is carried out analogously to Example 1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP05779438A 2004-09-22 2005-09-10 Lyophilisat enthaltend n-diaminomethylen-2-methyl-4,5-di-(methylsulfonyl)-benzamid Withdrawn EP1791528A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004045825A DE102004045825A1 (de) 2004-09-22 2004-09-22 Lyophilisat enthaltend N-Diaminomethylen-2-methyl-4,5-di-(methylsulfonyl)-benzamid
PCT/EP2005/009741 WO2006032386A1 (de) 2004-09-22 2005-09-10 Lyophilisat enthaltend n-diaminomethylen-2-methyl-4,5-di-(methylsulfonyl)-benzamid

Publications (1)

Publication Number Publication Date
EP1791528A1 true EP1791528A1 (de) 2007-06-06

Family

ID=35432481

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05779438A Withdrawn EP1791528A1 (de) 2004-09-22 2005-09-10 Lyophilisat enthaltend n-diaminomethylen-2-methyl-4,5-di-(methylsulfonyl)-benzamid

Country Status (7)

Country Link
US (1) US20070299139A1 (ja)
EP (1) EP1791528A1 (ja)
JP (1) JP2008513526A (ja)
AU (1) AU2005287591A1 (ja)
CA (1) CA2581081A1 (ja)
DE (1) DE102004045825A1 (ja)
WO (1) WO2006032386A1 (ja)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19529612A1 (de) * 1995-08-11 1997-02-13 Merck Patent Gmbh Sulfonyl- oder Sulfinyl-benzoylguanidin-Derivate
DE19903275A1 (de) * 1999-01-28 2000-08-03 Merck Patent Gmbh Lyophilisate mit verbesserter Rekonstituierbarkeit
KR20020066778A (ko) * 2001-02-13 2002-08-21 한국과학기술연구원 체내 난흡수 물질의 흡수촉진용 조성물과 제형 및 그의제조방법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006032386A1 *

Also Published As

Publication number Publication date
CA2581081A1 (en) 2006-03-30
JP2008513526A (ja) 2008-05-01
US20070299139A1 (en) 2007-12-27
WO2006032386A1 (de) 2006-03-30
AU2005287591A1 (en) 2006-03-30
DE102004045825A1 (de) 2006-03-23

Similar Documents

Publication Publication Date Title
DE3536896C2 (de) Lyophilisiertes, ein Anthracyclinglycosid enthaltendes pharmazeutisches Präparat und Verfahren zur Herstellung einer sterilen injizierbaren Lösung hieraus
DE60132108T2 (de) Gefriergetrocknetes pantoprazol-präparat und pantoprazol-injektion
KR920003331B1 (ko) 활성성분으로 스페르구알린(Spergualin)을 함유하는 주사제 조성물과 그 제조방법.
DE3729863A1 (de) Stabilisierte erythropoietin-lyophilisate
EP3272361B1 (de) Verfahren zur herstellung einer gefriergetrockneten pharmazeutischen zusammensetzung mit gehalt an mitomycin c
DE2219635C3 (de) Insulinsalz-Protamin-Komplexe und Verfahren zu ihrer Herstellung
EP0806955B1 (de) Enrofloxacin-injektions- oder infusionslösungen
DE112012003995T5 (de) Caspofunginpräparat mit geringem Verunreinigungsgehalt, Verfahren zu seiner Herstellung und seine Verwendung
EP2620153B1 (en) 5 alpha-androstane (alkyl)-3 beta,5,6 beta-triol injection and preparation method therefor
DE112012003996T5 (de) Caspofunginpräparat mit geringem Verunreinigungsgehalt, Verfahren zu seiner Herstellung und seine Verwendung
DE60009926T2 (de) Stabilisierung von gefriergetrocknetem kuchen
DD296417A5 (de) Wasserloesliche pharmazeutische metallocen-komplex-zusammensetzung
DE19529057B4 (de) Ifosfamid-Lyophilisat-Zubereitungen
DE2515001C2 (de) Prostaglandin enthaltende gefriergetrocknete Pulver
DE2719690A1 (de) Stabilisierte prostaglandinzubereitung und verfahren zur herstellung derselben
CH647677A5 (de) 4'-(acridinylamino)-methansulfon-anisidid enthaltende pharmazeutische zusammensetzung.
DE602005002742T2 (de) Verfahren zur stabilisierung von ungeordnetem cefovecin-natriumsalz
DE2423811A1 (de) Verfahren zur herstellung von gefriergetrockneten 2,2'-anhydro-1-beta-d-arabinofuranosylcytosin-praeparaten und injektionspraeparat
WO2006032386A1 (de) Lyophilisat enthaltend n-diaminomethylen-2-methyl-4,5-di-(methylsulfonyl)-benzamid
EP1638532A1 (de) Injizierbare darreichungsform von flupirtin
EP1479389B1 (de) Gebrauchsfertige Gemcitabin-Lösungen
EP0400609A1 (de) Intravenöse Lösungen mit schnellem Wirkungseintritt
EP0684840B1 (de) Verfahren zur herstellung kolloidaler wässriger lösungen schwerlöslicher wirkstoffe und ein lipid dafür
DE2729903A1 (de) Antithrombosemittel
DE2441761A1 (de) Gefriergetrocknete 2,2'-anhydro1-beta-d-arabinofuranosylcytosinsalz-praeparate, verfahren zu ihrer herstellung und injektionspraeparat

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070125

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KRESS, DOROTHEE

Inventor name: MAHLER, HANNS-CHRISTIAN

Inventor name: SCHIROKY, DIRK

Inventor name: HECKMANN, RITA

17Q First examination report despatched

Effective date: 20070727

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080207